Summary

Report Scope
The global market for chronic kidney disease is segmented by technology type, pharmaceutical drugs, and end users. From a technological perspective, the market is divided into diagnostic, therapeutic, and renal replacement solutions. Diagnostic technologies encompass biomarker-driven assays, imaging techniques, point-of-care testing, and genomic and proteomic screening, which facilitate early diagnosis and ongoing disease assessment. Therapeutic technologies encompass conventional drug treatments, innovative cell- and gene-based therapies, and advanced drug delivery systems, designed to slow disease progression and enhance patient outcomes. Renal replacement technologies, such as hemodialysis, peritoneal dialysis, and bioengineered artificial kidneys, are predominantly utilized in late-stage and end-stage CKD management.
In terms of pharmaceutical drugs, the market is segmented by CKD stage (Stage 1-5) and by medications used for dialysis and post-transplant care. This segmentation reflects the varying therapeutic requirements associated with disease severity and treatment settings. Based on end users, the market is classified into hospitals, clinics, and home-based or in-house dialysis settings. Hospitals and clinics account for the largest share due to comprehensive care capabilities, but the home care segment is experiencing rapid growth driven by increased patient preference, convenience, and advances in dialysis technologies. For market estimates, data has been provided for 2024 as the base year, 2025 as the estimated year, and with forecasts for 2026 through 2030.
Report Includes
- 57 data tables and 43 additional tables
- In-depth analysis of the global markets for chronic kidney diseases (CKD) and related technologies
- Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue forecasts, along with a corresponding market share analysis by product type, application, end-user and region
- Facts and figures pertaining to the market dynamics, technological advances, regulations, prospects, reimbursement practices, and the impact of macroeconomic variables
- Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
- Information on current state of chronic kidney disease, with an emphasis on biomarkers, diagnostic methods and mobile apps that support effective disease state management
- Key insight into research on CKD comorbidities such as diabetes and metabolic disease, as well as treatment methods and diagnostics
- Review of key granted and published patents
- Analysis of the industry structure, including companies’ shares and global rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Company profiles of major players within the industry, including Fresenius Medical Care AG, Baxter, B. Braun SE, NIPRO, and Medtronic

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Overview
Macroeconomic Factors Analysis
Growth in Healthcare Spending and Focus on Chronic Conditions
Aging Populations and Shifting Demographic Patterns
Economic Development, Urbanization, and Lifestyle-Related Health Risks
Investment in Healthcare Infrastructure and Broader Access to Care
Impact of U.S. Tariffs and Global Trade Dynamics
Porter’s Five Forces Analysis
Potential for New Entrants to the Market
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of Substitutes
Competition in the Industry
Chapter 3 Market Dynamics
Overview
Market Drivers
Growing Prevalence of Chronic Diseases Such as Diabetes and Hypertension Globally
Progression Rate from Early-Stage CKD to End-Stage Renal Disease (ESRD)
Increased Number of Dialysis Centers and Laboratories
Market Restraints
High Capital and High Cost of Treatment and Limited Reimbursement
Stringent Regulatory and Approval Requirements
Low Awareness and Late Diagnosis
Market Opportunities
Growing Investment in Regenerative Medicine and Biologic Therapies
Expanding Research and Development Efforts by Industry Leaders
Research and Development Initiatives from Key Companies
Chapter 4 Regulatory Landscape
Overview
Regulatory Scenario in the U.S.
Regulatory Scenario in Europe
Regulatory Scenario in Asia-Pacific
Japan
China
India
Regulatory Scenario in the Rest of the World
Chapter 5 Emerging Technologies and Patent Analysis
Overview
Emerging Trends/Technologies
Advanced Diagnostic Technologies
Novel Therapeutics and Biologics
Wearable and Implantable Renal Devices
Artificial Intelligence, Machine Learning, and Digital Health
Regenerative Medicine and Tissue Engineering
Patent Analysis
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Breakdown by Technology
Takeaways
Diagnostic Technologies
Therapeutic Technologies
Renal Replacement Technologies
Market Breakdown by Pharmaceutical Drugs
Takeaways
Market Breakdown by End User
Takeaways
Geographic Breakdown
Market Breakdown by Region
Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa
South America
Chapter 7 Competitive Intelligence
Competitive Analysis
Strategic Analysis
Investment Landscape
Chapter 8 Sustainability in the Chronic Kidney Disease Market: ESG Perspective
Overview
Sustainability Trends and Initiatives of AI in the Chronic Kidney Disease Industry
ESG Risk Ratings
Concluding Remarks from BCC Research
Chapter 9 Appendix
Research Methodology
Abbreviations
References
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTELLAS PHARMA INC.
BAXTER
BAYER AG
B. BRAUN SE
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
FRESENIUS MEDICAL CARE AG
JOHNSON & JOHNSON
LILLY USA LLC
NOVARTIS AG
PFIZER INC.
SIEMENS HEALTHINEERS AG
THERMO FISHER SCIENTIFIC INC.
TORAY INDUSTRIES INC.
Emerging Startups/Market Disruptors

ページTOPに戻る

List of Tables/Graphs

List of Tables
Summary Table : Global Market for Chronic Kidney Disease, by Region, Through 2030
Table 1 : U.S. Regulatory Pathways for Chronic Kidney Disease Market
Table 2 : European Regulatory Pathways for Chronic Kidney Disease Market
Table 3 : Global Regulatory Summary for Chronic Kidney Disease Market
Table 4 : Global Market for Chronic Kidney Diseases, by Technology, Through 2030
Table 5 : Global Market for Chronic Kidney Diseases, by Diagnostic Technology, Through 2030
Table 6 : Global Market for Chronic Kidney Disease, by Therapeutic Technology, Through 2030
Table 7 : Global Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
Table 8 : Global Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
Table 9 : Global Market for Chronic Kidney Disease, by End User, Through 2030
Table 10 : Global Market for Chronic Kidney Disease, by Region, Through 2030
Table 11 : North American Market for Chronic Kidney Disease, by Technology, Through 2030
Table 12 : North American Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
Table 13 : North American Market for Chronic Kidney Disease, by Therapeutic Technology, Through 2030
Table 14 : North American Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
Table 15 : North American Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
Table 16 : North American Market for Chronic Kidney Disease, by End User, Through 2030
Table 17 : North American Market for Chronic Kidney Disease, by Country, Through 2030
Table 18 : European Market for Chronic Kidney Disease, by Technology, Through 2030
Table 19 : European Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
Table 20 : European Market for Chronic Kidney Diseases, by Therapeutic Technology, Through 2030
Table 21 : European Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
Table 22 : European Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
Table 23 : European Market for Chronic Kidney Diseases, by End User, Through 2030
Table 24 : European Market for Chronic Kidney Disease, by Country, Through 2030
Table 25 : Asia-Pacific Market for Chronic Kidney Disease, by Technology, Through 2030
Table 26 : Asia-Pacific Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
Table 27 : Asia-Pacific Market for Chronic Kidney Disease, by Therapeutic Technology, Through 2030
Table 28 : Asia-Pacific Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
Table 29 : Asia-Pacific Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
Table 30 : Asia-Pacific Market for Chronic Kidney Disease, by End User, Through 2030
Table 31 : Asia-Pacific Market for Chronic Kidney Disease, by Country, Through 2030
Table 32 : MEA Market for Chronic Kidney Disease, by Technology, Through 2030
Table 33 : MEA Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
Table 34 : MEA Market for Chronic Kidney Diseases, by Therapeutic Technology, Through 2030
Table 35 : MEA Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
Table 36 : MEA Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
Table 37 : MEA Market for Chronic Kidney Disease, by End User, Through 2030
Table 38 : MEA Market for Chronic Kidney Disease, by Country, Through 2030
Table 39 : South American Market for Chronic Kidney Disease, by Technology, Through 2030
Table 40 : South American Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
Table 41 : South American Market for Chronic Kidney Disease, by Therapeutic Technology, Through 2030
Table 42 : South American Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
Table 43 : South American Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
Table 44 : South American Market for Chronic Kidney Disease, by End User, Through 2030
Table 45 : South American Market for Chronic Kidney Disease, by Country, Through 2030
Table 46 : Agreements, Collaborations, and Partnerships in the Chronic Kidney Diseases Market, 2023–2025
Table 47 : ESG Risk Rankings for Chronic Kidney Disease Market, 2025*
Table 48 : Abbreviations Used in this Report
Table 49 : AbbVie Inc.: Company Snapshot
Table 50 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 51 : AbbVie Inc.: Product Portfolio
Table 52 : AbbVie Inc.: News/Key Developments, 2023–2025
Table 53 : Amgen Inc.: Company Snapshot
Table 54 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 55 : Amgen Inc.: Product Portfolio
Table 56 : Amgen Inc.: News/Key Developments, 2023–2025
Table 57 : Astellas Pharma Inc.: Company Snapshot
Table 58 : Astellas Pharma Inc.: Financial Performance, FY 2023 and 2024
Table 59 : Astellas Pharma Inc.: Product Portfolio
Table 60 : Baxter: Company Snapshot
Table 61 : Baxter: Financial Performance, FY 2023 and 2024
Table 62 : Baxter: Product Portfolio
Table 63 : Baxter: News/Key Developments, 2024 and 2025
Table 64 : Bayer AG: Company Snapshot
Table 65 : Bayer AG: Financial Performance, FY 2023 and 2024
Table 66 : Bayer AG: Product Portfolio
Table 67 : B. Braun SE: Company Snapshot
Table 68 : B. Braun SE: Financial Performance, FY 2023 and 2024
Table 69 : B. Braun SE: Product Portfolio
Table 70 : Boehringer Ingelheim International GmbH: Company Snapshot
Table 71 : Boehringer Ingelheim International GmbH: Product Portfolio
Table 72 : Boehringer Ingelheim International GmbH: News/Key Developments, 2023–2024
Table 73 : Fresenius Medical Care AG: Company Snapshot
Table 74 : Fresenius Medical Care AG: Financial Performance, FY 2023 and 2024
Table 75 : Fresenius Medical Care AG: Product Portfolio
Table 76 : Fresenius Medical Care AG: News/Key Developments, 2024 and 2025
Table 77 : Johnson & Johnson: Company Snapshot
Table 78 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 79 : Johnson & Johnson: Product Portfolio
Table 80 : Lilly USA LLC: Company Snapshot
Table 81 : Lilly USA LLC: Financial Performance, FY 2023 and 2024
Table 82 : Lilly USA LLC: Product Portfolio
Table 83 : Novartis AG: Company Snapshot
Table 84 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 85 : Novartis AG: Product Portfolio
Table 86 : Pfizer Inc.: Company Snapshot
Table 87 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 88 : Pfizer Inc.: Product Portfolio
Table 89 : Pfizer Inc.: News/Key Developments, 2025
Table 90 : Siemens Healthineers AG: Company Snapshot
Table 91 : Siemens Healthineers AG: Financial Performance, FY 2024 and 2025
Table 92 : Siemens Healthineers AG: Product Portfolio
Table 93 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 94 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 95 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 96 : Toray Industries Inc.: Company Snapshot
Table 97 : Toray Industries Inc.: Financial Performance, FY 2023 and 2024
Table 98 : Toray Industries Inc.: Product Portfolio
Table 99 : List of a Few Emerging Startups in the Global Chronic Kidney Disease MarketList of Figures
Summary Figure : Global Market Shares for Chronic Kidney Disease, by Region, 2024
Figure 1 : Porter’s Five Forces Analysis: Chronic Kidney Disease Market
Figure 2 : Market Dynamics of Chronic Kidney Disease
Figure 3 : Patent Shares for Chronic Kidney Disease Market, by Jurisdiction, 2025
Figure 4 : Global Market Shares for Chronic Kidney Diseases, by Technology, 2024
Figure 5 : Global Market Shares for Chronic Kidney Diseases, by Diagnostic Technology, 2024
Figure 6 : Global Market Shares for Chronic Kidney Diseases, by Therapeutic Technology, 2024
Figure 7 : Global Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
Figure 8 : Global Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
Figure 9 : Global Market Shares for Chronic Kidney Disease, by End User, 2024
Figure 10 : Global Market Shares for Chronic Kidney Disease, by Region, 2024
Figure 11 : North American Market Shares for Chronic Kidney Disease, by Technology, 2024
Figure 12 : North American Market Shares for Chronic Kidney Disease, by Diagnostic Technology, 2024
Figure 13 : North American Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
Figure 14 : North American Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
Figure 15 : North American Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
Figure 16 : North American Market Shares for Chronic Kidney Disease, by End User, 2024
Figure 17 : North American Market Shares for Chronic Kidney Disease, by Country, 2024
Figure 18 : European Market Shares for Chronic Kidney Disease, by Technology, 2024
Figure 19 : European Market Shares for Chronic Kidney Disease, by Diagnostic Technology, 2024
Figure 20 : European Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
Figure 21 : European Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
Figure 22 : European Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
Figure 23 : European Market Shares for Chronic Kidney Disease, by End User, 2024
Figure 24 : European Market Shares for Chronic Kidney Disease, by Country, 2024
Figure 25 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Technology, 2024
Figure 26 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Diagnostic Technology, 2024
Figure 27 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
Figure 28 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
Figure 29 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
Figure 30 : Asia-Pacific Market Shares for Chronic Kidney Disease, by End User, 2024
Figure 31 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Country, 2024
Figure 32 : MEA Market Shares for Chronic Kidney Diseases, by Technology, 2024
Figure 33 : MEA Market Shares for Chronic Kidney Diseases, by Diagnostic Technology, 2024
Figure 34 : MEA Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
Figure 35 : MEA Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
Figure 36 : MEA Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
Figure 37 : MEA Market Shares for Chronic Kidney Disease, by End User, 2024
Figure 38 : MEA Market Shares for Chronic Kidney Disease, by Country, 2024
Figure 39 : South American Market Shares for Chronic Kidney Disease, by Technology, 2024
Figure 40 : South American Market Shares for Chronic Kidney Disease, by Diagnostic Technology, 2024
Figure 41 : South American Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
Figure 42 : South American Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
Figure 43 : South American Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
Figure 44 : South American Market Shares for Chronic Kidney Disease, by End User, 2024
Figure 45 : South American Market Shares for Chronic Kidney Disease, by Country, 2024
Figure 46 : Global Market Shares for Chronic Kidney Diseases, by Leading Companies, 2024
Figure 47 : AbbVie Inc: Revenue Share, by Country/Region, FY 2024
Figure 48 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 49 : Astellas Pharma Inc.: Revenue Share, by Business Unit, FY 2024
Figure 50 : Astellas Pharma Inc.: Revenue Share, by Country/Region, FY 2024
Figure 51 : BAXTER: Revenue Share, by Business Unit, FY 2024
Figure 52 : BAXTER: Revenue Share, by Country/Region, FY 2024
Figure 53 : Bayer AG: Revenue Share, by Business Unit, FY 2024
Figure 54 : Bayer AG: Revenue Share, by Country/Region, FY 2024
Figure 55 : B. Braun SE: Revenue Share, by Business Unit, FY 2024
Figure 56 : B. Braun SE: Revenue Share, by Country/Region, FY 2024
Figure 57 : Fresenius Medical Care AG: Revenue Share, by Business Unit, FY 2024
Figure 58 : Fresenius Medical Care AG: Revenue Share, by Country/Region, FY 2024
Figure 59 : Johnson & Johnson: Revenue Share, by Business Unit, FY 2024
Figure 60 : Johnson & Johnson: Revenue Share, by Country/Region, FY 2024
Figure 61 : Lilly USA LLC: Revenue Share, by Country/Region, FY 2024
Figure 62 : Novartis AG: Revenue Share, by Business Unit, FY 2024
Figure 63 : Novartis AG: Revenue Share, by Country/Region, FY 2024
Figure 64 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
Figure 65 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
Figure 66 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2025
Figure 67 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2025
Figure 68 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024
Figure 69 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024
Figure 70 : Toray Industries Inc.: Revenue Share, by Business Unit, FY 2024
Figure 71 : Toray Industries Inc.: Revenue Share, by Country/Region, FY 2024